DYADIC INTERNATIONAL, INC.

DYAI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $3.1M $3.5M $2.9M $2.9M $2.4M $1.6M $1.7M
Cost of Revenue $2.3M $1.2M $2.0M $2.1M $1.9M $1.4M $1.5M
Gross Profit $770.5K $2.3M $923.0K $807.1K $459.4K $177.0K $221.4K
Gross Margin 24.9% 65.8% 31.8% 27.5% 19.1% 11.0% 13.2%
Operating Expenses
Research & Development $2.2M $2.0M $3.3M $4.5M $8.4M $3.9M $3.1M
SG&A Expense $5.8M $6.1M $5.8M $6.4M $6.7M $6.1M $5.5M
Operating Income $-7.2M $-5.9M $-8.2M $-10.2M $-14.7M $-10.0M $-9.3M
Operating Margin -232.8% -168.8% -283.9% -346.9% -612.7% -625.9% -552.2%
Interest Expense
Pretax Income
Income Tax Expense $0 $31.3K $10.3K
Net Income $-7.4M $-5.8M $-6.8M $-9.7M $-13.1M $-9.3M $-8.3M
Net Margin -238.3% -166.2% -234.4% -332.2% -543.7% -582.1% -494.2%
EPS (Basic) $-0.23 $-0.20 $-0.24 $-0.34 $-0.47 $-0.34 $-0.31
EPS (Diluted) $-0.23 $-0.20 $-0.47 $-0.34 $-0.31
Shares Outstanding (Basic) 36.4M 28.8M 28.4M 28.2M 27.5M 27.4M
Shares Outstanding (Diluted) 36.4M 32.6M 29.3M 28.8M 28.4M 28.2M 27.5M 27.4M
Dividends Per Share
← Newer Page 1 of 2 Older →